Biotech company Dendreon Corp. (DNDN.O: Quote, Profile, Research) said on Thursday it plans to seek approval from the U.S. Food and Drug Administration later this year to market the prostate cancer drug Provenge.
The company said results of a Phase 3 study of the drug would appear in the July issue of the Journal of Clinical Oncology. Provenge is an active cellular immunotherapy designed to stimulate the immune system with minimal side effects.
